Biocon Limited (NSE:BIOCON)
India
· Delayed Price · Currency is INR 354.40
+3.90 (1.11%)
Jun 27, 2025, 3:30 PM IST
Biocon Revenue
In the fiscal year ending March 31, 2025, Biocon had annual revenue of 152.62B INR with 3.43% growth. Biocon had revenue of 44.17B in the quarter ending March 31, 2025, with 12.76% growth.
Revenue
152.62B
Revenue Growth
+3.43%
P/S Ratio
2.68
Revenue / Employee
9.35M
Employees
16,315
Market Cap
409.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 152.62B | 5.06B | 3.43% |
| Mar 31, 2024 | 147.56B | 35.82B | 32.05% |
| Mar 31, 2023 | 111.74B | 29.90B | 36.54% |
| Mar 31, 2022 | 81.84B | 10.41B | 14.57% |
| Mar 31, 2021 | 71.43B | 8.43B | 13.37% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Biocon News
- 1 day ago - Biocon subsidiary gets Health Canada nod for YESAFILI - Business Upturn
- 12 days ago - Biocon shares in focus as company reportedly plans to launch QIP to raise up to Rs 4,500 crore - Business Upturn
- 19 days ago - Biocon launches BioWISE program to empower women in STEM across Karnataka - Business Upturn
- 25 days ago - Top stocks to watch today, June 3: HCLTech, Mphasis, Britannia Industries, Torrent Power, Biocon and more - Business Upturn
- 25 days ago - Stocks to watch on June 3: Biocon, PTC India Financial, HCL Tech, Yes Bank, Maruti, Reliance Infra, Aptus Value, Zinka Logistics, Adani Group in focus - Business Upturn
- 25 days ago - Biocon receives CDSCO approval for its Liraglutide drug in India - Business Upturn
- 4 weeks ago - ‘Metro Mentor’ moment: Kiran Mazumdar-Shaw ditches car, hops on Bengaluru Metro with Exxon Mobil’s ‘Iron Lady’; calls ride ‘quick way to avoid traffic’ - The Times of India
- 4 weeks ago - Biocon Biologics receives UK MHRA approval for YESINTEK, Biosimilar Ustekinumab - Business Upturn